The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study

Tetsuji Kurokawa, Makoto Yamamoto, Toshimichi Onuma, Hideaki Tsuyoshi, Akiko Shinagawa, Yoko Chino, Yoshio Yoshida, Tetsuji Kurokawa, Makoto Yamamoto, Toshimichi Onuma, Hideaki Tsuyoshi, Akiko Shinagawa, Yoko Chino, Yoshio Yoshida

Abstract

Background: In general, human papillomavirus (HPV) vaccines have demonstrated efficacy in young women worldwide, but there is limited evidence on the efficacy of the quadrivalent HPV6/11/16/18 vaccine in adult women and no evidence of its effectiveness in Japanese adult women in particular. This study aims to evaluate the efficacy of the quadrivalent HPV6/11/16/18 vaccine for persistent HPV16/18 infection in Japanese women aged 27-45 years.

Methods: This is an interventional, nonrandomized, non-double-blind prospective cohort study designed to compare the rates of persistent HPV16/18 infection between the vaccinated arm and unvaccinated arm. The subjects will consist of all women aged 27-45 years who have normal cytology results confirmed by cervical cancer screening from May 2019 to March 2021. The follow-up time is two years. The subjects will be divided into two groups: the vaccinated group and the unvaccinated group. The study will need to enroll 600 vaccinated participants (experimental arm) and 2200 unvaccinated participants (control arm).

Discussion: The findings of this trial (HAKUOH study) might provide the first local evidence on the subject and be significantly useful not only to medical academia but also to the Japanese Ministry of Health, Labour and Welfare. The findings could contribute to public health improvement by providing local supportive knowledge on the prevention of HPV infection through HPV vaccination in young adult women in Japan, where active recommendations have been suspended for a long time due to adverse effects.

Trial registration: Trial registration number: NCT04022148 . Registration began on December 1, 2019.

Keywords: Catch-up program; Cervical cancer; Human papillomavirus; Vaccine.

Conflict of interest statement

Tetsuji Kurokawa received lecture fees from MSD. All other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Study design. IC*: IC to participant in the study and to be sent the recommendation for vaccination

References

    1. Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, et al. Bivalent human papillomavirus vaccine effectiveness in a Japanese population: high vaccine-type-specific effectiveness and evidence of cross-protection. J Infect Dis. 2019;219(3):382–390. doi: 10.1093/infdis/jiy516.
    1. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571. doi: 10.1016/S0140-6736(15)61152-7.
    1. Larson HJ, Hartigan-Go K, de Figueiredo A. Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness. Hum Vaccin Immunother. 2019;15(3):625–627. doi: 10.1080/21645515.2018.1522468.
    1. Tanaka Y, Ueda Y, Egawa-Takata T, Yagi A, Yoshino K, Kimura T. Outcomes for girls without HPV vaccination in Japan. Lancet Oncol. 2016;17(7):868–869. doi: 10.1016/S1470-2045(16)00147-9.
    1. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213–2227. doi: 10.1016/S0140-6736(14)60920-X.
    1. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154–1168. doi: 10.1016/S1473-3099(16)30120-7.
    1. Kurokawa T, Onuma T, Shinagawa A, Chino Y, Kobayashi M, Yoshida Y. The ideal strategy for cervical cancer screening in Japan: result from the Fukui cervical Cancer screening study. Cytopathology. 2018;29(4):361–367. doi: 10.1111/cyt.12576.
    1. Yu LL, Guo HQ, Lei XQ, Qin Y, Wu ZN, Kang LN, et al. p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China. Oncotarget. 2016;7(40):64810–64819. doi: 10.18632/oncotarget.11705.
    1. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105(1):28–37. doi: 10.1038/bjc.2011.185.
    1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943. doi: 10.1056/NEJMoa061760.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere